62 Entries

World Health Assembly certified global eradication. Only human disease ever eradicated through vaccination.

Awarded for discovery of the major histocompatibility complex (MHC), which determines how immune cells present antigens -- critical for understanding variable vaccine responses across populations.

Scientists at Chiron Corporation and UC San Francisco expressed hepatitis B surface antigen in yeast cells, pioneering recombinant DNA vaccine technology. The recombinant HepB vaccine was licensed in 1986.

First vaccine targeting a cause of cancer. Initially derived from plasma of infected donors.

Founded as Dissatisfied Parents Together after the DPT: Vaccine Roulette documentary. Later renamed the National Vaccine Information Center. Became one of the most visible U.S. organizations questioning vaccine safety and advocating for informed consent.

Media portrayal leading to NVIC founding and litigation surge.

NBC aired DPT: Vaccine Roulette, a documentary alleging that the DTP vaccine caused brain damage in children. Prompted formation of the NVIC and contributed to the 1986 NCVIA legislation.

Fauci served as director of the National Institute of Allergy and Infectious Diseases for 38 years, guiding the U.S. response to HIV/AIDS, Ebola, Zika, and COVID-19. Served as a primary public spokesperson for the U.S. federal pandemic response during COVID-19.

Takahashi developed Oka strain live attenuated vaccine in Japan (1974). Licensed in Japan 1984, US 1995.

Awarded for immune system theories and the technique for producing monoclonal antibodies. Monoclonal antibody technology became essential for vaccine quality control and diagnostics.

Polysaccharide vaccine. Later replaced by conjugate vaccines.

The Pan American Health Organization adopted the goal of eliminating wild poliovirus from the Western Hemisphere by 1990, launching intensified vaccination campaigns across Latin America.

Robbins and Schneerson at NIH developed the conjugate vaccine concept, chemically linking Hib polysaccharide to a protein carrier to generate immune responses in infants. This technology later enabled PCV and meningococcal conjugate vaccines.

NCVIA established VICP, VAERS, VIS.

The NCVIA mandated creation of a national adverse event reporting system. VAERS formally launched in 1990 as a joint FDA-CDC passive surveillance system.

FDA established comprehensive GMP requirements specifically for biological products including vaccines, standardizing manufacturing quality controls across the industry.

FDA licensed Recombivax HB (Merck), the first recombinant vaccine, replacing the plasma-derived hepatitis B vaccine. Produced in yeast cells using recombinant DNA technology.

First vaccine produced using recombinant DNA technology (yeast-derived). Replaced plasma-derived version.

Protein-conjugated Hib vaccine. Dramatically reduced Hib meningitis in children.

GPEI launched to eradicate polio worldwide. Wild polio cases dropped from 350,000 (1988) to single digits.

The World Health Assembly adopted a resolution to eradicate polio globally by the year 2000 -- later revised as challenges persisted in conflict zones and areas with weak health infrastructure.

The Vaccine Injury Compensation Program, established by the 1986 NCVIA, began accepting injury claims. Created a no-fault system funded by a $0.75-per-antigen excise tax on vaccines.

A major measles resurgence with over 55,000 cases and 136 deaths between 1989-1991, primarily among unvaccinated preschoolers and young adults. Led to the two-dose MMR recommendation.

Licensed in Australia for at-risk workers.

Ty21a live oral typhoid vaccine (Vivotif) licensed in the U.S., offering an alternative to the injectable Vi polysaccharide vaccine for travelers to endemic areas.

ACIP recommended a second dose of MMR vaccine, typically at age 4-6, after the 1989-1991 measles resurgence demonstrated that a single dose was insufficient for population-level immunity.

ACIP recommended routine Hib conjugate vaccination for all infants beginning at 2 months of age. Hib meningitis cases declined by over 99% within a decade.

Passive and active surveillance systems launched.

The UN World Summit for Children set goals of 90% childhood vaccination coverage and polio eradication by 2000, mobilizing political commitment and resources for global immunization.

The WHO/UNICEF Universal Childhood Immunization initiative reached its target of 80% global DTP3 coverage, up from less than 20% in the early 1980s.

Independent teams demonstrated that viral capsid proteins could self-assemble into virus-like particles, creating highly immunogenic but non-infectious vaccine candidates. VLP technology underpins HPV and HepB vaccines.

Frazer and Zhou created virus-like particles (VLPs) that mimicked the HPV virus, enabling the development of the HPV vaccine. Zhou died in 1999 before seeing the vaccine reach market.

ACIP recommended universal hepatitis B vaccination beginning at birth, expanding the vaccine from high-risk-group-only use to the routine childhood schedule.

Three-year-old Luis Fermin Tenorio of Peru was the last person in the Americas to contract wild poliovirus, detected on August 23, 1991.

Inactivated hepatitis A vaccine.

Mandatory military vaccination program controversy.

Squalene antibody allegations in Gulf War veterans.

Approximately 1 additional GBS case per million vaccinated.

Aseptic meningitis from Urabe mumps strain.

Federal entitlement program created to provide vaccines at no cost to children who are uninsured, Medicaid-eligible, American Indian/Alaska Native, or underinsured. Removed cost as a barrier to childhood vaccination.

The IOM (now National Academies) published its landmark review of adverse events associated with childhood vaccines, establishing the evidence framework still used to evaluate vaccine-injury claims.

Western Hemisphere declared free of wild poliovirus.

The varicella (chickenpox) vaccine, developed by Takahashi in Japan in 1974, was licensed in the U.S. in 1995 after extensive clinical trials. Made the U.S. the first country to include varicella in the routine childhood schedule.

The European Medicines Agency began operations in London (later relocated to Amsterdam), centralizing pharmaceutical regulation across EU member states including vaccine approvals.

ACIP, AAP, and AAFP jointly published the first unified childhood immunization schedule, ending decades of occasional discrepancies between organizations' separate recommendations.

Chickenpox vaccine added to U.S. childhood schedule.

ACIP recommended hepatitis A vaccination for children in high-incidence states and communities, later expanding to universal childhood recommendation in 2006.

Awarded for discovering how the immune system recognizes virus-infected cells through MHC restriction. Foundational for understanding T-cell responses to vaccination.

FDA licensed DTaP for primary series use in U.S. infants, replacing the more reactogenic whole-cell DTP vaccine. ACIP recommended DTaP as preferred pertussis vaccine in 1997.

Multiple childhood vaccine shortages occurred as manufacturers exited the market due to liability costs and low profit margins. Highlighted the vulnerability of the U.S. vaccine supply chain.

France suspended school-based HepB vaccination.

First and only human Lyme disease vaccine. Approximately 78% effective.

Licensed August 1998. Withdrawn October 1999.

First rotavirus vaccine RotaShield (Wyeth) was licensed in August 1998 and recommended by ACIP. Withdrawn in 1999 after intussusception signal.

Aluminum persistence at injection sites described.

Paper later found to contain ethical violations, lack of institutional approval, and scientific misrepresentation. Retracted 2010. License revoked.

Withdrawn despite no confirmed safety problem.

Precautionary removal from childhood vaccines.

Australia first linked family assistance payments to compliance with the childhood vaccination schedule in 1998, creating financial incentives for vaccination. Conscientious objection was permitted until the No Jab, No Pay legislation of 2016 removed non-medical exemptions.

Intussusception. 98 confirmed cases.

ACIP recommended transitioning from oral polio vaccine (OPV) to inactivated polio vaccine (IPV) for routine immunization to eliminate the risk of vaccine-associated paralytic poliomyelitis (VAPP).

Ended OPV use in U.S. to eliminate VAPP.